Diagnosis of diseases of the central nervous system by means of PET and SPECT: Radiopharmaceutical strategies and clinical applications;Radiopharmazeutische strategien und klinische anwendungen: Diagnostik von ZNS-erkrankungen mittels PET bzw. SPECT

Pharmazie in Unserer Zeit

Volumn 34, Issue 6, 2005, Pages 474-482

  Rösch, Frank ^a   Gründer, Gerhard ^b   Schreckenberger, Matthias ^b   Dannhardt, Gerd ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IODINE 123; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; TRACER;

ALZHEIMER DISEASE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; DIAGNOSTIC TEST; DOPAMINERGIC SYSTEM; EPILEPSY; HUMAN; INTERMETHOD COMPARISON; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 28544446939     PISSN: 00483664     EISSN: None     Source Type: Journal    
DOI: 10.1002/pauz.200500145     Document Type: Article

References (16)

1. Garnett, E.S., Firnau, G., Nahmias, C.: Dopamine visualized in the basal ganglia of living man. Nature 305 (1983), 137-138.
2. Frey, K.A., Koeppe, R.A., Kilbourn, M.R.: Imaging the vesicular monoamine transporter. Adv. Neurol. 86 (2001), 237-47.
3. Herholz, K., Herscovitch, P., Heiss, W.-D.: NeuroPET: Positron Emission tomography in neuroscience and clinical neurology, Springer, Berlin, Heidelberg (2004).
4. 18F]desmethoxyfallypride. J. Nucl. Med. 44 (2003), 109-116.
5. Herholz, K., Salmon, E., Perani, D., Baron, J.C., Holthoff, V., Frolich, L., Schonknecht, P., Ito, K., Mielke, R., Kalbe, E., Zundorf, G., Delbeuck, X., Pelati, O., Anchisi, D., Fazio, F., Kerrouche, N., Desgranges, B., Eustache, F., Beuthien-Baumann, B., Menzel, C., Schroder, J., Kato, T., Arahata, Y., Henze, M., Heiss, W.D.: Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17 (2002), 302-3156.
6. Silverman, D.H., Small, G.W., Chang, C.Y., Lu, C.S., Kung De Aburto, M.A., Chen, W., Czernin, J., Rapoport, S.I., Pietrini, P., Alexander, G.E., Schapiro, M.B., Jagust, W.J., Hoffman, J.M., Welsh-Bohmer, K.A., Alavi, A., Clark, C.M., Salmon, E., de Leon, M.J., Mielke, R., Cummings, J.L., Kowell, A.P., Gambhir, S.S., Hoh, C.K., Phelps, M.E.: Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286 (2001), 2120-2127.
7. Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, Sudo Y, Suzuki K, Irie T.: Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 349 (1997), 1805-1809.
8. Rinne, J.O., Kaasinen, V., Jarvenpaa, T., Nagren, K., Roivainen, A., Yu, M., Oikonen, V., Kurki, T.: Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 74 (2003), 113-115.
9. Mulholland, G.K., Wieland, D.M., Kilbourn, M.R., Frey, K.A., Sherman, P.S., Carey, J.E., Kühl, D.E.: [18F]fluoroethoxy-benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses. Synapse 30 (1998), 263-274.
10. Kikuchi, T., Zhang, M.R., Ikota, N., Fukushi, K., Okamura, T., Suzuki, K., Arano, Y., Irie, T.: N-[18F]fluoroethylpiperidin-4ylmethyl acetate, a novel lipophilic acetylcholine analogue for PET measurement of brain acetylcholinesterase activity. J. Med. Chem. 48 (2005), 2577-2583.
11. Wang, Y., Klunk, W.E., Huang, G.F., Debnath, M.L., Hunag, G.-F., Holt, D.P., Shao, L., Mathis, C.A.: Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease. J. Mol. Neurosci. 24 (2004), 055-062.
12. Beer, H.F., Bläuenstein, P.A., Häusler, P.H., Delaloye, B., Riccabona, G., Bangerl, I., Hunkeler, W., Bonetti, E. P., Pieri, L., Richards, J. G.: In vitro and in vivo evaluation of Iodine-123-Ro 16-0154: A new imaging agent for SPECT investigations of benzodiazepine receptors. J. Nucl. Med. 31 (1990), 1007-1014.
13. 18F]fluoroethylflumazenil: a novel tracer for PET imaging of human benzodiazepine receptors. Eur. J. Nucl. Med. 28 (2001), 1463-1470.
14. Heinz, A., Siessmeier, T., Wrase, J., Hermann, D., Klein, S., Grüsser, S. M., Flor, H., Braus, D. F., Buchholz, H.-G., Gründer, G., Schreckenberger, M., Smolka, M. N., Rösch, F., Mann, K., Bartenstein, P.: Correlation between dopamine D2 receptors in the ventral striatum and central processing of alcohol cues and craving. Am. J. Psychiatry 161 (2004), 1783-1789.
15. Farde, L, Nordström, A. L., Wiesel, F. A., Pauli, S., Halldin, C., Sedvall, G.: Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49 (1992), 538-544.
16. Gründer, G., Vernaleken, I., Müller, M. J., Davids, E., Heydari, N., Buchholz, H.-G., Bartenstein, P., Munk, O., Stoeter, P., Wong, D. F., Gjedde, A., Cumming, P.: Subchronic haloperidol downregulates dopamine synthesis capacity in brain of schizophrenic patients in vivo. Neuropsychopharmacology 28 (2003), 787-794.